Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Design of a Novel Nanocarrier Technology to Drug-Load CAR T cells

Award Number: R01CA284065
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2023
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Design of a Novel Nanocarrier Technology to Drug-Load CAR T cells - Project summary: Current treatment for Glioblastoma Multiforme (GBM), the most common malignant brain tumor in adults, involves maximal safe resection, followed by adjuvant chemoradiation. Although this treatment is life prolonging, it is never curative. Five year survival is less than 7 %1 and improved therapies are urgently needed. In this proposal, we aim to develop a new targeted therapy with reduced toxicity and increased efficacy for GBM patients by leveraging nanotechnology discoveries in our laboratory to improve adoptive cell therapy. Chimeric Antigen Receptor (CAR) T cells combine the cytolytic potency of a T cell with the tumor specificity of an antibody. Recent clinical trial experiences of CAR T cells in solid tumors have identified the immune-suppressive tumor microenvironment (TME) as a major barrier to clinical success2-4. One immune-suppressive endogenous negative regulator in GBM TME is TGFβ, which has been identified as barrier to CAR T tumor eradication. Small molecule inhibitors of the TGFβ receptor as well as TGFβ resistant CAR T cells have been developed and tested clinically, however they are limited due to systemic toxicity. Herein we propose developing a platform technology to drug-load CAR T cells with nanocarriers, thus enhancing the therapeutic window of CAR T cells, and addressing one of the major obstacles to CAR T cells in brain tumors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $574,360 )
2025	2025	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	3901 RAINBOW BLVD	KANSAS CITY	KS	66160	WYANDOTTE	USA	Cancer Treatment Research	000	3	6/13/2025	NON-COMPETING CONTINUATION	$574,360
														Subtotal = $574,360

Issue Date FY: 2024 ( Subtotal = $545,643 )
2024	2024	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	3901 RAINBOW BLVD	KANSAS CITY	KS	66160	WYANDOTTE	USA	Cancer Treatment Research	000	2	7/1/2024	NON-COMPETING CONTINUATION	$545,643
														Subtotal = $545,643

Issue Date FY: 2023 ( Subtotal = $574,360 )
2023	2023	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	3901 RAINBOW BLVD	KANSAS CITY	KS	66160	WYANDOTTE	USA	Cancer Treatment Research	000	1	6/28/2023	NEW	$574,360
														Subtotal = $574,360

Grand Total All Awards = $1,694,363

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Design of a Novel Nanocarrier Technology to Drug-Load CAR T cells

Award Number: R01CA284065

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2023

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer